Skip to main content

Table 2 Vemurafenib pharmacokinetics in the pharmacokinetic cohort

From: Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

  

Vemurafenib (N = 20)

Study day

Parameter

Mean ± SD

CV %

Day 1

AUC0-8h, μg·h/mL

37.5 ± 22.3

59.4

AUC0-12h, μg·h/mL

57.5 ± 32.6

56.7

Cmax, μg/mL

6.9 ± 3.9

55.8

Day 15

Ctrough, μg/mL

63.0 ± 23.3

37.0

Day 21

AUC0-8h, μg·h/mL

501.3 ± 123.0

24.5

AUC0-12h, μg·h/mL

720.3 ± 185.8

25.8

Cmax, μg/mL

77.6 ± 17.9

23.0

Ctrough, μg/mL

72.6 ± 20.0

27.5

t½, h

35.6 ± 18.1

Accumulation ratio

17.9 ± 14.1

  1. SD standard deviation, CV coefficient of variation, AUC 0-8h area under the concentration-time curve from 0 to 8 h, AUC 0-12h area under the concentration-time curve from 0 to 12 h, C max maximal plasma concentration, C trough plasma trough concentration, t ½ terminal half-life, accumulation ratio AUC0-8h on day 21/AUC0-8h on day 1